PDCD1 and non-small cell lung carcinoma: Results obtained with programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown remarkable and durable clinical activity in patients with advanced NSCLC, with few adverse reactions [9].